Company's new implantable bone device can save up to $28k per patient

Biologics

Swedish-based bone graft substitute manufacturer Bonesupport, which received FDA approval for its bone infection indicator Cerament G in May, has found that the new product saves an average of $28,000 per patient according to a Nov. 21 email sent to Becker's. 

The Cerament G implantable device/drug combination provides a pathway for a single-stage approach to bone infections for those susceptible to bone fractures and foot ulcers. 

Surgeons and hospitals can receive up to 65 percent reimbursement when using Cerament G, according to the email. Reimbursement is only applicable to Medicare patients. 

Treatment cost savings are due to the product's effectiveness, which reduces the need for follow-up procedures and post-surgical complications. 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers